Sign in
Taking people in United StatesNo phase

How spinal cord stimulators affect restless legs syndrome

Studies nerve and brain responses in people with restless legs syndrome or chronic pain.

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Registry title
The Effect of Spinal Cord Stimulators on Restless Leg Syndrome
Status
Recruiting
People taking part
50 people, planned
Started
4 Aug 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • H-Reflex
  • Somatosensory evoked potential (SSEP)
  • Vibratory Electrophysiological Response Potential (ERP)
  • Transcranial Magnetic Stimulation (TMS)
  • Spinal Cord Stimulator (SCS) manipulation
Record updated
26 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Restless Legs Syndrome (RLS), with or without a spinal cord stimulator (SCS). It also takes people with chronic pain who have an SCS but no RLS, and healthy people without RLS.

Age
18 Years and older
Sex
All sexes
Disease stage
People with RLS. Some groups must already have an SCS or be scheduled to get one. One group has chronic pain and an SCS but no RLS.
Earlier treatment
No major changes in RLS medicines in the past 4 weeks. Cannot be using another device to treat RLS.

Main reasons for not taking part

  • Pregnant, breastfeeding, or trying to become pregnant
  • Spinal cord injury, epilepsy or seizures, multiple sclerosis, or deep vein thrombosis
  • Severe nerve damage, severe movement disorder such as Parkinson's disease, or severe mental or memory problems
  • Cancer in the past 5 years (except basal cell or squamous cell skin cancer), or drug or alcohol abuse in the past year
  • Current active or long-lasting infection other than the common cold

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Has Restless Leg Syndrome
  • No major changes in RLS medications in past 4 weeks
  • Willing and able to comply with study protocol
  • Healthy Controls - No RLS diagnosis
  • Ability to provide informed consent

Who cannot take part

  • Currently using another device to treat RLS
  • Other medical condition that would put the subject at risk as determined by the investigator
  • One or more of the following diseases: spinal cord injury, severe peripheral neuropathy or radiculopathy, severe psychiatric or cognitive disorder that may interfere with participation of the study, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than the common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e. Parkinson's disease), deep vein thrombosis, or multiple sclerosis
  • Any mental or physical limitation that would prevent completing any of the studies
  • Unable or unwilling to comply with study protocols
  • Pregnant, breastfeeding, or trying to become pregnant
  • Currently participating or planning to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigator, affect RLS

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Marshall Holland, MDTaking people

About the trial

What the trial wants to find out

This study aims to evaluate neurophysiological responses and symptom changes in individuals with Restless Legs Syndrome (RLS) and/or chronic pain. Participants will undergo standard clinical assessments including EEG, EMG, h-reflex, SSEP, ERP, and TMS under varying SCS conditions.The study involves 4 arms. Arm 1 are individuals diagnosed with RLS and Healthy Controls. Arm 2 are individuals diagnosed with RLS and have an existing SCS. Arm 3 are individuals diagnosed with RLS and scheduled to receive a SCS. Arm 4 are individuals with chronic pain and have a SCS, but no diagnosis of RLS.

The 4 groups in the trial

  • Arm 1: Assessments and questionnaires onlyExisting treatment, for comparison

    Complete questionnaires on RLS and pain Stimulation: H-reflex - A small electrical stimulus is provided to the leg and foot area and a measurement of the stimulus is taken by the EEG electrodes. Somatosensory evoked potential (SSEP) - A small electrical stimulus is provided to a nerve on the body and measured at several places along the nervous system (spinal cord, brain, etc.) with the EMG and EEG electrodes. Vibratory Electrophysiological Response Potential (ERP) - stimulation of the ankle with vibration sensations using a device like a buzzer and recording of body's responses using the EEG and/or EMG electrodes. Transcranial Magnetic Stimulation (TMS) - A small magnetic pulse is used to provide a small amount of electrical stimulation to nervous system. The EEG and/or EMG electrodes will be used to measure body's reaction.

    Treatment: H-Reflex, Somatosensory evoked potential (SSEP), Vibratory Electrophysiological Response Potential (ERP), and Transcranial Magnetic Stimulation (TMS)

  • Arm 2: Off-on-offExisting treatment, for comparison

    Participants will turn OFF their SCS at least 48 hours prior to the visit. The assessments listed in Arm 1 will be performed and the SCS will be turned ON for at least 60 minutes before repeating the assessments. Participants may repeat the questionnaires during this waiting period. Finally, the SCS is turned OFF again, this time for at least 30 minutes before repeating the assessments, except for the h-reflex, which will not be needed again. As with before, participants can complete the questionnaires during this waiting period.

    Treatment: H-Reflex, Somatosensory evoked potential (SSEP), Vibratory Electrophysiological Response Potential (ERP), Transcranial Magnetic Stimulation (TMS), and Spinal Cord Stimulator (SCS) manipulation

  • Arm 3: Off-on-off post-opExisting treatment, for comparison

    Participants will perform the same procedures as those in Arm 2, but only after 2-3 weeks from receiving a permanent SCS.

    Treatment: H-Reflex, Somatosensory evoked potential (SSEP), Vibratory Electrophysiological Response Potential (ERP), Transcranial Magnetic Stimulation (TMS), and Spinal Cord Stimulator (SCS) manipulation

  • Arm 4: On-off-onExisting treatment, for comparison

    Participants will have their SCS on for at least 48 hours prior to the visit. The assessments listed in Arm 1 will be performed and the SCS will be turned Off for at least 60 minutes before repeating the assessments. Participants may repeat the questionnaires during this waiting period. Finally, the SCS is turned On again, this time for at least 30 minutes before repeating the assessments, except for the h-reflex, which will not be needed again. As with before, participants can complete the questionnaires during this waiting period.

    Treatment: H-Reflex, Somatosensory evoked potential (SSEP), Vibratory Electrophysiological Response Potential (ERP), Transcranial Magnetic Stimulation (TMS), and Spinal Cord Stimulator (SCS) manipulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Spinal Cord Stimulators on Restless Leg Syndrome
Plain-language title
How spinal cord stimulators affect restless legs syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
26 June 2026